Taipei, Taiwan, 4 July, 2025 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795) today announced that its subsidiary, Alvogen Korea Co., Ltd (“Alvogen Korea”), has received a written judgement from the Seoul High Court, ruling in favour and overturned allegations by the Korea’s Fair-Trade Commission of collusion for its products Arimidex and Casodex.
With the favourable ruling, it is expected that the fines for Alvogen Korea corresponding to the products totaling around KRW500 million will be cancelled.
Petar Vazharov, Chief Executive Officer of Lotus Pharmaceutical, commented:
"We are pleased with the favourable outcomes from this ruling, which reflects Lotus’ dedication to lawful and ethical business practices. We remain steadfast in our commitment to providing high-quality, affordable medications to patients while upholding the highest standards of compliance and ethical conduct."
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.
Media Inquiries:
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com